Bristol-Myers Squibb Rises 5% Following FDA Approval of Schizophrenia Drug

Bristol-Myers Squibb Shares Rise 5% Following FDA Approval of Schizophrenia Medication

Bristol-Myers Squibb experienced a 5% increase in its stock value after receiving approval from the FDA for its new drug aimed at treating schizophrenia. The approval marks a significant milestone for the company in its efforts to expand its pharmaceutical portfolio and address the needs of patients suffering from this mental health disorder. Investors reacted positively to the news, reflecting optimism about the potential impact of this drug on the company’s growth trajectory.